A detailed history of Marathon Capital Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Marathon Capital Management holds 6,407 shares of ABBV stock, worth $1.12 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
6,407
Previous 6,422 0.23%
Holding current value
$1.12 Million
Previous $1.1 Million 14.9%
% of portfolio
0.32%
Previous 0.29%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $2,457 - $2,989
-15 Reduced 0.23%
6,407 $1.27 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $31,731 - $37,055
205 Added 3.3%
6,422 $1.1 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $7,991 - $9,105
-50 Reduced 0.8%
6,217 $1.13 Million
Q4 2023

Feb 08, 2024

SELL
$137.6 - $154.97 $30,960 - $34,868
-225 Reduced 3.47%
6,267 $971,000
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $20,038 - $23,197
-150 Reduced 2.26%
6,492 $967,000
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $9,010 - $11,213
-68 Reduced 1.01%
6,642 $894,000
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $3.26 Million - $3.76 Million
-22,555 Reduced 77.07%
6,710 $1.07 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $21,299 - $25,543
-154 Reduced 0.52%
29,265 $4.73 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $23,755 - $27,245
-177 Reduced 0.6%
29,419 $3.95 Million
Q2 2022

Aug 12, 2022

BUY
$137.62 - $174.96 $16,652 - $21,170
121 Added 0.41%
29,596 $4.53 Million
Q1 2022

May 13, 2022

SELL
$131.98 - $163.75 $31,939 - $39,627
-242 Reduced 0.81%
29,475 $4.78 Million
Q4 2021

Feb 09, 2022

SELL
$107.43 - $135.93 $21,271 - $26,914
-198 Reduced 0.66%
29,717 $4.02 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $5,320 - $6,039
50 Added 0.17%
29,915 $3.23 Million
Q2 2021

Aug 16, 2021

SELL
$105.21 - $117.21 $13,151 - $14,651
-125 Reduced 0.42%
29,865 $3.36 Million
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $136,059 - $149,784
1,330 Added 4.64%
29,990 $3.25 Million
Q4 2020

Feb 08, 2021

BUY
$80.49 - $108.67 $106,649 - $143,987
1,325 Added 4.85%
28,660 $3.07 Million
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $83,848 - $98,410
-976 Reduced 3.45%
27,335 $2.39 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $86,209 - $115,361
1,175 Added 4.33%
28,311 $2.78 Million
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $66,757 - $101,212
1,035 Added 3.97%
27,136 $2.07 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $1.24 Million - $1.55 Million
17,185 Added 192.74%
26,101 $2.31 Million
Q3 2019

Nov 13, 2019

BUY
$62.98 - $75.72 $561,529 - $675,119
8,916 New
8,916 $675,000
Q2 2019

Jul 25, 2019

SELL
$65.7 - $83.98 $165,301 - $211,293
-2,516 Closed
0 $0
Q4 2018

Feb 07, 2019

BUY
$77.85 - $96.01 $12,066 - $14,881
155 Added 6.57%
2,516 $231,000
Q1 2018

May 07, 2018

SELL
$92.01 - $123.21 $13,801 - $18,481
-150 Reduced 5.97%
2,361 $223,000
Q3 2017

Nov 13, 2017

BUY
$69.85 - $89.22 $175,393 - $224,031
2,511
2,511 $223,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Marathon Capital Management Portfolio

Follow Marathon Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marathon Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Marathon Capital Management with notifications on news.